Compare Chipotle Mexican Grill, Inc. (CMG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Novo Nordisk A/S — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.65 (market cap $40.49B), while Novo Nordisk A/S trades at $46.25 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.1× Chipotle Mexican Grill, Inc.'s market cap, and Novo Nordisk A/S pays a 3.81% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.
| CMG | NVO | |
|---|---|---|
Market Cap | $40.49B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $63.98 |
52-Week Low | $28.17 | $35.29 |
Enterprise Value | $45.24B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $32.25, up 0.34% on the day, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds from a recent salmonella outbreak linked to jalapeños, contributing to a 12.64% weekly drop. Fundamentally, revenue growth remains robust, reaching $11.93B in 2025, with strong profitability metrics including a 49.56% ROE. Analyst consensus is overwhelmingly bullish with a $42.17 price target, though technical indicators show selling pressure with key support at $32.
The outlook for CMG balances strong fundamentals against near-term operational risks. Wall Street's buy ratings (70.15%) reflect confidence in long-term growth, but recent food safety issues and declining net income margins pose immediate challenges. Investors should weigh the company's consistent revenue trajectory against potential volatility from ongoing outbreaks and rising costs.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
